10x Genomics director granted 8,829 RSUs
Kosaraju Sridhar reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kosaraju Sridhar reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Sridhar Kosaraju reported a stock-based compensation award. He received a grant of 8,829 shares of Class A Common Stock as restricted stock units (RSUs) at no cash cost. After this grant, he holds 65,278 shares directly.
The RSUs vest in four equal installments on each quarterly anniversary starting on May 21, 2026, as long as he continues as a service provider through each vesting date. The filing also shows 3,000 Class A shares held indirectly through the Kosaraju Family Trust, where he serves as trustee.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 8,829 | $0.00 | $0.00 |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.
- F2. These shares are held by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
Class A Common Stock financial
quarterly anniversary financial
service provider financial
Family Trust financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did 10x Genomics (TXG) director Sridhar Kosaraju report in this Form 4?
What is the vesting schedule for Sridhar Kosaraju’s 10x Genomics (TXG) RSUs?
Are Sridhar Kosaraju’s new 10x Genomics (TXG) RSUs an open-market purchase?
AI-generated analysis. How Rhea-AI works. Not financial advice.